Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255501 | 0.78 | — | — | |
| SCHEMBL25754774 | 0.71 | — | — | |
| SCHEMBL6398084 | 0.70 | — | — | |
| Quinoline SCHEMBL28096917 | 0.69 | ALDH1A1 (0.53) | DRD2DRD3 | |
| SCHEMBL7873570 | 0.68 | NISCH (0.34) | — | |
| SCHEMBL21505362 | 0.67 | HTR2A (0.33) | GRIN1GRIN2BDRD2DRD3NOS3 | |
| SCHEMBL56690 | 0.67 | TRPA1 (0.42) | NOS3NOS2 | |
| SCHEMBL29376431 | 0.67 | — | — | |
| SCHEMBL17297299 | 0.67 | — | — | |
| SCHEMBL31408049 | 0.67 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | claimed |
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024120505-A1 | FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF, AND USE THEREOF | 上海枢境生物科技有限公司 | 2024-06-13 | — | — | WO | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| EP-3365334-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| CN-104583195-B | Nitrogenous heteroaromatic ring derivative as tyrosine kinase inhibitor | 山东亨利医药科技有限责任公司 | 2018-08-17 | — | — | CN | disclosed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-106794161-A | TrkA kinase inhibitors, composition and its method | 默沙东公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| CN-104968664-A | BICYCLIC COMPOUND FUNCTIONING AS TYROSINE KINASE INHIBITOR | KBP BIOSCIENCES CO LTD | 2015-10-07 | — | — | CN | disclosed |
| CN-104583195-A | Nitrogen-containing heteroaromatic ring derivative as tyrosine kinase inhibitor | KBP BIOSCIENCES CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-102372692-B | Dihydropyridine derivative | KBP BIOSCIENCES CO LTD | 2014-02-26 | — | — | CN | disclosed |
| CN-103347876-A | Aniline substituted quinazoline derivative and preparation method and application thereof | KBP BIOSCIENCES CO LTD | 2013-10-09 | — | — | CN | disclosed |
| WO-2013102145-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | GRIN2D 4464/4885GRIN3B 4421/4885GRIN1 2364/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | GRIN2D 4464/4885GRIN3B 4421/4885GRIN1 2364/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | GRIN2D 4470/4885GRIN3B 4449/4885GRIN1 2354/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | GRIN2D 4510/4885GRIN3B 4463/4885GRIN1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.